Sign In
Buy INVA
$21.70
+0.350 (+1.64%)
At Close: Jun 03, 2026
Innoviva to Participate in Upcoming Investor Conferences
12:01pm, Monday, 01'st Jun 2026
Innoviva, Inc. (NASDAQ: INVA) (âInnovivaâ or the âCompanyâ), a diversified biopharmaceutical company with a core royalties portfolio, a leading critica
Innoviva to Participate in Upcoming Investor Conferences
11:00am, Monday, 01'st Jun 2026
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical ca
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
06:35pm, Friday, 29'th May 2026
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.
Innoviva (INVA) Tops Q1 Earnings Estimates
10:45pm, Wednesday, 06'th May 2026
Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
04:05pm, Wednesday, 06'th May 2026
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical ca
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
08:41am, Thursday, 30'th Apr 2026
Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
04:10am, Saturday, 18'th Apr 2026
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One equit
3 Bargain-Cheap Small Caps Worth a Second Look
08:24am, Thursday, 09'th Apr 2026
The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.
Innoviva (NASDAQ:INVA) Shares Cross Above 200 Day Moving Average – Here’s What Happened
03:20am, Tuesday, 07'th Apr 2026
Innoviva, Inc. (NASDAQ: INVA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $20.50 and tra
Analysts Set Innoviva, Inc. (NASDAQ:INVA) Price Target at $34.80
01:31am, Friday, 27'th Mar 2026
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat Ratings report
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
05:37pm, Friday, 27'th Feb 2026
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva, Inc. (NASDAQ:INVA) Receives Average Recommendation of “Moderate Buy” from Brokerages
04:34am, Friday, 27'th Feb 2026
Innoviva, Inc. (NASDAQ: INVA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the company, MarketBeat Ratings report
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
04:05pm, Wednesday, 25'th Feb 2026
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical ca
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Thursday, 19'th Feb 2026
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
